Papers
1
Total Citations
15
H-Index
1
About
Dr. Paige Xu is a distinguished urologic oncologist and researcher whose work centers on improving prostate cancer diagnosis and treatment through advanced imaging and biopsy techniques. Her most impactful contribution, the 2019 study "Downgrading of Grade Group After Radical Prostatectomy," compares multiparametric magnetic resonance imaging (mpMRI) guided fusion biopsy with the standard 12-core biopsy approach. This research, cited 15 times, demonstrates how fusion biopsy more accurately predicts final pathology after radical prostatectomy, reducing the risk of overtreatment by identifying patients who may safely avoid aggressive therapy. Dr. Xu’s findings have practical implications for clinical decision-making, helping to refine risk stratification and personalize treatment plans. Her work bridges radiology and pathology, highlighting the value of integrating mpMRI into routine prostate cancer care. By showing that fusion biopsy leads to less grade group downgrading post-surgery, she has provided evidence that supports its adoption as a more reliable diagnostic tool. Dr. Xu’s research continues to influence urologic practice, offering clearer guidance for both clinicians and patients navigating prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1